{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "VATC" in comments (approximate match)
Status:
US Previously Marketed
Source:
Xigris
(2001)
Source URL:
First approved in 2001
Source:
Xigris
Source URL:
Class:
PROTEIN
Status:
US Previously Marketed
Source:
Neumega
(1997)
Source URL:
First approved in 1997
Source:
Neumega
Source URL:
Class:
PROTEIN
Status:
US Previously Marketed
Source:
Infergen
(1997)
Source URL:
First approved in 1997
Source:
Infergen
Source URL:
Class:
PROTEIN
Status:
US Previously Marketed
Source:
TRASYLOL by BAYER HLTHCARE
(1993)
Source URL:
First approved in 1993
Source:
TRASYLOL by BAYER HLTHCARE
Source URL:
Class:
PROTEIN
Status:
First approved in 1991
Class:
PROTEIN
Status:
US Previously Marketed
Source:
GEREF by EMD SERONO
(1990)
Source URL:
First approved in 1990
Source:
GEREF by EMD SERONO
Source URL:
Class:
PROTEIN
Conditions:
Sermorelin, a 29 amino acid analog of human growth hormone-releasing hormone (GHRH), is the shortest synthetic peptide with a full biological activity of GHRH which is used as a diagnostic agent to assess growth hormone (GH) secretion for the purpose of diagnosing growth hormone deficiency. Intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary. Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion. Hormone responses to intravenous sermorelin appear to be a rapid and relatively specific test for the diagnosis of growth hormone deficiency.
Status:
US Previously Marketed
Source:
CIBACALCIN by NOVARTIS
(1986)
Source URL:
First approved in 1986
Source:
CIBACALCIN by NOVARTIS
Source URL:
Class:
PROTEIN
Status:
First approved in 1985
Class:
PROTEIN
Status:
US Previously Marketed
Source:
CHYMODIACTIN by DISCURE MEDICAL, LLC
(1982)
Source URL:
First approved in 1982
Source:
CHYMODIACTIN by DISCURE MEDICAL, LLC
Source URL:
Class:
PROTEIN
